Keyword: Ajovy

Teva's Copaxone is losing ground to generic competition—and the company's newer drugs aren’t taking off fast enough to make up for the loss.

UnitedHealthcare's pharmacy benefits outfit OptumRx picked Amgen and Eli Lilly CGRP drugs for its preferred coverage list, handing Teva a setback.

Despite new competition from CGRP migraine prevention drugs, Allergan executives contend Botox can continue to grow.

CVS' coverage decision for Amgen's Aimovig marks a setback for the company's launch and a boost for rivals Teva and Eli Lilly.

What kind of difference can one year make? Just ask some Teva analysts, who are upbeat that the drugmaker's cost-cutting measures are paying off.

England's National Institute for Health and Care Excellence says available clinical data aren't enough to demonstrate Aimovig's cost-effectiveness.

Despite its CGRP drug Emgality's third-to-market status, Lilly has big plans for a growing stable of migraine and pain drugs, an exec said.

The FDA has handed Lilly’s Emgality a 'breakthrough' nod in cluster headaches. Lilly plans to file for approval in that use by the end of the year.

Concerns about discounting on Teva's migraine drug Ajovy are high as the company's generics unit and MS blockbuster falter.

Allergan and Eli Lilly won coverage from PBM giant Express Scripts for their new migraine launches, but Teva's Ajovy was left out in the cold.